The Diagnostic division has been established to specifically target new and existing genetic testing technologies in already established networks that will provide direct access to medically qualified doctors. These will be made commercially available to other laboratory pathology service providers and the diagnostic tests will be used to complement their existing tests.

Predictive and presymptomatic tests will also be developed to detect gene mutations associated with disorders in people who have a family member with a genetic disorder, but who have no features of the disorder themselves at the time of testing. Predictive testing can identify mutations that increase a person's chances of developing disorders with a genetic basis, such as certain types of cancer. Presymptomatic testing can determine whether a person will develop a genetic disorder, such as haemochromatosis (an iron overload disorder), before any signs or symptoms appear. The results of predictive and presymptomatic testing can provide information about a person’s risk of developing a specific disorder and help with making decisions about medical care.

As part of the service being offered, we will provide counselling through medical qualified professionals to assist consumers in understanding the significance of the tests.

Diagnostic testing is used to diagnose or rule out a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical mutations and symptoms. Diagnostic testing can be performed at any time during a person's life, but is not available for all genes or all genetic conditions. The results of a diagnostic test can influence a person's choices about health care and the management of the disease.

Diagnostic tests through SecureDNA will be made available to the market in the coming months.